WO2000056317A1 - Weight loss after pregnancy - Google Patents

Weight loss after pregnancy Download PDF

Info

Publication number
WO2000056317A1
WO2000056317A1 PCT/US2000/007202 US0007202W WO0056317A1 WO 2000056317 A1 WO2000056317 A1 WO 2000056317A1 US 0007202 W US0007202 W US 0007202W WO 0056317 A1 WO0056317 A1 WO 0056317A1
Authority
WO
WIPO (PCT)
Prior art keywords
compound
formula
cyclobutyl
chlorophenyl
methylbutylamine
Prior art date
Application number
PCT/US2000/007202
Other languages
French (fr)
Inventor
Carl M. Mendel
Timothy B. Seaton
Steve P. Weinstein
Original Assignee
Knoll Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to KR1020017011956A priority Critical patent/KR20010113848A/en
Application filed by Knoll Gmbh filed Critical Knoll Gmbh
Priority to MXPA01009465A priority patent/MXPA01009465A/en
Priority to IL14524300A priority patent/IL145243A0/en
Priority to CA002367268A priority patent/CA2367268A1/en
Priority to BR0009078-6A priority patent/BR0009078A/en
Priority to PL00351080A priority patent/PL351080A1/en
Priority to AU41729/00A priority patent/AU4172900A/en
Priority to JP2000606222A priority patent/JP2002539253A/en
Priority to EP00921401A priority patent/EP1162966A4/en
Priority to SK1336-2001A priority patent/SK13362001A3/en
Publication of WO2000056317A1 publication Critical patent/WO2000056317A1/en
Priority to NO20014474A priority patent/NO20014474L/en
Priority to BG105995A priority patent/BG105995A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone

Definitions

  • This invention relates to a method of aiding weight loss after pregnancy.
  • R, and R 2 are independently H or methyl, is administered in conjunction with a pharmaceutically acceptable diluent or carrier to a human in need thereof.
  • a preferred compound of formula I isjsl,N-dimethyl-1-[1-(4- chlorophenyl)cyclobutyl]-3-methylbutylamine or a salt thereof, for example the hydrochloride salt.
  • a preferred form of this hydrochloride is its monohydrate.
  • N,N-dimethyl-1-[1-(4-chlorophenyl)cyclobutyl]-3- methylbutylamine hydrochloride in the treatment of obesity is described in published PCT application WO90/06110.
  • a particularly preferred form of this compound is N, N-dimethyl-1 -[1 -(4-chlorophenyl)cyclobutyl]-3-methylbutylamine hydrochloride monohydrate (sibutramine hydrochloride) which is described in European Patent Number 230742.
  • the enantiomers may be resolved by methods known to those skilled in the art, for example by formation of diastereoisomeric salts or complexes which may be separated, for example, by crystallisation; via formation of diastereoisomeric derivatives which may be separated, for example, by crystallisation, gas-liquid or liquid chromatography; selective reaction of one enantiomer with an enantiomer- specific reagent, for example enzymatic oxidation or reduction, followed by separation of the modified and unmodified enantiomers; or gas-liquid or liquid chromatography in a chiral environment, for example on a chiral support, for example silica with a bound chiral ligand or in the presence of a chiral solvent.
  • enantiomers may be synthesised by asymmetric synthesis using optically active reagents, substrates, catalysts or solvents, or by converting one enantiomer to the other by asymmetric transformation.
  • Preferred compounds of formula I are N.N-dimethyl-1-[1-(4-chlorophenyl)- cyclobutyl]-3-methylbutylamine, N- ⁇ 1 -[1 -(4-chlorophenyl)cyclobutyl]-3- methylbutyl ⁇ -N- methylamine, and 1-[1-(4-chlorophenyl)cyclobutyl]-3- methylbutyiamine including racemates, individual enantiomers and mixtures thereof, and pharmaceutically acceptable salts thereof.
  • the individual enantiomers can be prepared by enantioselective synthesis from optically active precursors, or by resolving the racemic compound which can be prepared as described above.
  • Enantiomers of secondary amines of the formula I can also be prepared by preparing the racemate of the corresponding primary amine, resolving the latter into the individual enantiomers, and then converting the optically pure primary amine enantiomer into the required secondary amine by methods described in British Patent Specification 2098602.
  • hydrochloride salts are preferred in each case, but the free bases and other pharmaceutically acceptable salts are also suitable.
  • the compound of formula I may be administered in any of the known pharmaceutical dosage forms.
  • the amount of the compound to be administered will depend on a number of factors including the age of the patient, the severity of the condition and the past medical history of the patient and always lies within the sound discretion of the administering physician but it is generally envisaged that the dosage of the compound to be administered will be in the range 0.1 to 50 mg preferably 1 to 30 mg per day given in one or more doses.
  • Oral dosage forms are the preferred compositions for use in the present invention and these are the known pharmaceutical forms for such administration, for example tablets, capsules, granules, syrups and aqueous or oil suspensions.
  • the excipients used in the preparation of these compositions are the excipients known in the pharmacist's art.
  • Tablets may be prepared from a mixture of the active compound with fillers, for example calcium phosphate; disintegrating agents, for example maize starch; lubricating agents, for example magnesium stearate; binders, for example microcrystalline cellulose or polyvinylpyrrolidone and other optional ingredients known in the art to permit tableting the mixture by known methods.
  • the tablets may, if desired, be coated using known methods and excipients which may include enteric coating using for example hydroxypropylmethylcellulose phthalate.
  • the tablets may be formulated in a manner known to those skilled in the art so as to give a sustained release of the compounds of the present invention.
  • Such tablets may, if desired, be provided with enteric coatings by known methods, for example by the use of cellulose acetate phthalate.
  • capsules for example hard or soft gelatin capsules, containing the active compound with or without added excipients, may be prepared by known methods and, if desired, provided with enteric coatings in a known manner.
  • the contents of the capsule may be formulated using known methods so as to give sustained release of the active compound.
  • the tablets and capsules may conveniently each contain 1 to 50 mg of the active compound.
  • dosage forms for oral administration include, for example, aqueous suspensions containing the active compound in an aqueous medium in the presence of a non-toxic suspending agent such as sodium carboxy- methylcellulose, and oily suspensions containing a compound of the present invention in a suitable vegetable oil, for example arachis oil.
  • the active compound may be formulated into granules with or without additional excipients.
  • the granules may be ingested directly by the patient or they may be added to a suitable liquid carrier (for example, water) before ingestion.
  • the granules may contain disintegrants, eg an effervescent couple formed from an acid and a carbonate or bicarbonate salt to facilitate dispersion in the liquid medium.
  • the therapeutically active compounds of formula I may be formulated into a composition which the patient retains in his mouth so that the active compound is administered through the mucosa of the mouth.
  • Dosage forms suitable for rectal administration are the known pharmaceutical forms for such administration, for example, suppositories with cocoa butter or polyethylene glycol bases.
  • Dosage forms suitable for parenteral administration are the known pharmaceutical forms for such administration, for example sterile suspensions or sterile solutions in a suitable solvent.
  • Dosage forms for topical administration may comprise a matrix in which the pharmacologically active compounds of the present invention are dispersed so that the compounds are held in contact with the skin in order to administer the compounds transdermally.
  • a suitable transdermal composition may be prepared by mixing the pharmaceutically active compound with a topical vehicle, such as a mineral oil, petrolatum and/or a wax, e.g. paraffin wax or beeswax, together with a potential transdermal accelerant such as dimethyl sulphoxide or propylene glycol.
  • the active compounds may be dispersed in a pharmaceutically acceptable cream, gel or ointment base.
  • the amount of active compound contained in a topical formulation should be such that a therapeutically effective amount of the compound is delivered during the period of time for which the topical formulation is intended to be on the skin.
  • the therapeutically active compound of formula I may be formulated into a composition which is dispersed as an aerosol into the patients oral or nasal cavity.
  • Such aerosols may be administered from a pump pack or from a pressurised pack containing a volatile propellant.
  • the therapeutically active compounds of formula I used in the method of the present invention may also be administered by continuous infusion either from an external source, for example by intravenous infusion or from a source of the compound placed within the body.
  • Internal sources include implanted reservoirs containing the compound to be infused which is continuously released for example by osmosis and implants which may be (a) liquid such as an oily suspension of the compound to be infused for example in the form of a very sparingly water-soluble derivative such as a dodecanoate salt or a lipophilic ester or (b) solid in the form of an implanted support, for example of a synthetic resin or waxy material, for the compound to be infused.
  • the support may be a single body containing all the compound or a series of several bodies each containing part of the compound to be delivered.
  • the amount of active compound present in an internal source should be such that a therapeutically effective amount of the compound is delivered over a long period of time.
  • the compounds of the present invention in the form of particles of very small size, for example as obtained by fluid energy milling.
  • the active compound may, if desired, be associated with other compatible pharmacologically active ingredients.
  • the invention further provides the use of compounds of formula I in the manufacture of a medicament for aiding in weight loss after pregnancy.
  • the invention further provides a pharmaceutical composition for aiding in weight loss after pregnancy, comprising a compound of formula I in conjunction with a pharmaceutically acceptable diluent or carrier.
  • Pregnancy can result in excessive weight gain and retention.
  • a certain amount of weight gain during pregnancy is desirable.
  • weight gain beyond the desired amount is predominantly maternal adipose tissue. It is this fat tissue that, in large measure, accounts for the postpartum retention weight gained during pregnancy. This retention reflects a postpartum energy balance that does not lead to catabolism of the gained adipose tissues.
  • Administration of a compound of Formula I helps to change the energy balance.
  • Monoamine reuptake inhibitors have been used to treat certain of the disorders described in the present invention.
  • these compounds are known to suffer from a number of disadvantages. Firstly such compounds are not effective in all patients. Secondly where the compounds are effective they may not provide a complete cure of the disorder. Thirdly, there are many undesirable side-effects known with this type of compound. Such side-effects include nausea, sexual dysfunction, light headedness, somnolence, sweating, tremor, dry mouth, asthenia, insomnia, diarrhoea, headache, vomiting, anxiety, drowsiness, dizziness, fever, rash or allergic reactions, arthralgia, myalgia, convulsions, hypomania and mania.
  • ⁇ -HT serotonin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Emergency Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

A compound of formula (I) or a pharmaceutically acceptable salt thereof in which R1 and R2 are independently H or methyl (for example N,N-dimethyl-1-[1-(4-chlorophenyl)cyclobutyl]-3-methylbutyl amine hydrochloride optionally in the form of its monohydrate) is used for aiding weight loss after pregnancy.

Description

Weight Loss after Pregnancy
This invention relates to a method of aiding weight loss after pregnancy.
According to the present invention there is provided a method of aiding in weight loss after pregnancy, in which a therapeutically effective amount of a compound of formula I
CH,
Figure imgf000003_0001
including enantiomers and pharmaceutically acceptable salts thereof, in which R, and R2 are independently H or methyl, is administered in conjunction with a pharmaceutically acceptable diluent or carrier to a human in need thereof.
A preferred compound of formula I isjsl,N-dimethyl-1-[1-(4- chlorophenyl)cyclobutyl]-3-methylbutylamine or a salt thereof, for example the hydrochloride salt. A preferred form of this hydrochloride is its monohydrate.
The preparation and use of compounds of formula I, such asjSI N- dimethyl-1 -[1 -(4-chlorophenyl)cyclobutyl]-3-methylbutylamine, N-{1 -[1 -(4- chlorophenyl)-cyclobutyl]-3-methylbutyl}-N-methylamine, and 1 -[1 -(4- chlorophenyl)-cyclobutyl]-3-methylbutylamine and salts thereof, in the treatment of depression is described in British Patent Specification 2098602 and US Patent 4,522,328. The use of compounds of formula I such as_NlN-dimethyl-1-[1-(4- chlorophenyl)cyclobutyl]-3-methylbutylamine and salts thereof in the treatment of Parkinson's disease is described in published PCT application WO 88/06444. The use of N,N-dimethyl-1-[1-(4-chlorophenyl)cyclobutyl]-3-methylbutylamine and salts thereof in the treatment of cerebral function disorders is described in US Patent 4,939,175. The use of N,N-dimethyl-1-[1-(4-chlorophenyl)cyclobutyl]-3- methylbutylamine hydrochloride in the treatment of obesity is described in published PCT application WO90/06110. A particularly preferred form of this compound is N, N-dimethyl-1 -[1 -(4-chlorophenyl)cyclobutyl]-3-methylbutylamine hydrochloride monohydrate (sibutramine hydrochloride) which is described in European Patent Number 230742. The use of NlN-dimethyl-1-[1-(4- chlorophenyl)cyclobutyl]-3-methylbutylamine and salts thereof for improving the glucose tolerance of humans having Impaired Glucose Tolerance or Non-Insulin Dependent Diabetes Mellitus is described in published PCT application WO95/20949.
It will be appreciated by those skilled in the art that compounds of formula I contain a chiral centre. When a compound of formula I contains a single chiral centre it may exist in two enantiomeric forms. The present invention includes the use of the individual enantiomers and mixtures of the enantiomers. The enantiomers may be resolved by methods known to those skilled in the art, for example by formation of diastereoisomeric salts or complexes which may be separated, for example, by crystallisation; via formation of diastereoisomeric derivatives which may be separated, for example, by crystallisation, gas-liquid or liquid chromatography; selective reaction of one enantiomer with an enantiomer- specific reagent, for example enzymatic oxidation or reduction, followed by separation of the modified and unmodified enantiomers; or gas-liquid or liquid chromatography in a chiral environment, for example on a chiral support, for example silica with a bound chiral ligand or in the presence of a chiral solvent. It will be appreciated that where the desired enantiomer is converted into another chemical entity by one of the separation procedures described above, a further step is required to liberate the desired enantiomeric form. Alternatively, specific enantiomers may be synthesised by asymmetric synthesis using optically active reagents, substrates, catalysts or solvents, or by converting one enantiomer to the other by asymmetric transformation.
Preferred compounds of formula I are N.N-dimethyl-1-[1-(4-chlorophenyl)- cyclobutyl]-3-methylbutylamine, N-{1 -[1 -(4-chlorophenyl)cyclobutyl]-3- methylbutyl}-N- methylamine, and 1-[1-(4-chlorophenyl)cyclobutyl]-3- methylbutyiamine including racemates, individual enantiomers and mixtures thereof, and pharmaceutically acceptable salts thereof.
The individual enantiomers can be prepared by enantioselective synthesis from optically active precursors, or by resolving the racemic compound which can be prepared as described above. Enantiomers of secondary amines of the formula I can also be prepared by preparing the racemate of the corresponding primary amine, resolving the latter into the individual enantiomers, and then converting the optically pure primary amine enantiomer into the required secondary amine by methods described in British Patent Specification 2098602.
Specific examples of compounds of formula I are:
(+)-N-[1 -[1 -(4-chlorophenyl)cyclobutyl]-3-methylbutyl}-N-methylamine;
(-)-N-{1-[1-(4-chlorophenyl)cyclobutyl-3-methylbutyl}-N-methylamine;
(+)-1 -[1 -(4-chlorophenyl)cyclobutyl]-3-methylbutylamine;
(-)-1 -[1 -(4-chlorophenyl)cyclobutyl]-3-methylbutylamine;
(+)-N-{1-[1-(4-chlorophenyl)cyclobutyl]-3-methylbutyl}-N-N-dimethylamine; (-)-N-{1 -[1 -(4-chlorophenyl)cyclobutyl]-3-methylbutyl}-N-N-dimethylamine.
The hydrochloride salts are preferred in each case, but the free bases and other pharmaceutically acceptable salts are also suitable.
The compound of formula I may be administered in any of the known pharmaceutical dosage forms. The amount of the compound to be administered will depend on a number of factors including the age of the patient, the severity of the condition and the past medical history of the patient and always lies within the sound discretion of the administering physician but it is generally envisaged that the dosage of the compound to be administered will be in the range 0.1 to 50 mg preferably 1 to 30 mg per day given in one or more doses.
Oral dosage forms are the preferred compositions for use in the present invention and these are the known pharmaceutical forms for such administration, for example tablets, capsules, granules, syrups and aqueous or oil suspensions. The excipients used in the preparation of these compositions are the excipients known in the pharmacist's art. Tablets may be prepared from a mixture of the active compound with fillers, for example calcium phosphate; disintegrating agents, for example maize starch; lubricating agents, for example magnesium stearate; binders, for example microcrystalline cellulose or polyvinylpyrrolidone and other optional ingredients known in the art to permit tableting the mixture by known methods. The tablets may, if desired, be coated using known methods and excipients which may include enteric coating using for example hydroxypropylmethylcellulose phthalate. The tablets may be formulated in a manner known to those skilled in the art so as to give a sustained release of the compounds of the present invention. Such tablets may, if desired, be provided with enteric coatings by known methods, for example by the use of cellulose acetate phthalate. Similarly, capsules, for example hard or soft gelatin capsules, containing the active compound with or without added excipients, may be prepared by known methods and, if desired, provided with enteric coatings in a known manner. The contents of the capsule may be formulated using known methods so as to give sustained release of the active compound. The tablets and capsules may conveniently each contain 1 to 50 mg of the active compound.
Other dosage forms for oral administration include, for example, aqueous suspensions containing the active compound in an aqueous medium in the presence of a non-toxic suspending agent such as sodium carboxy- methylcellulose, and oily suspensions containing a compound of the present invention in a suitable vegetable oil, for example arachis oil. The active compound may be formulated into granules with or without additional excipients. The granules may be ingested directly by the patient or they may be added to a suitable liquid carrier (for example, water) before ingestion. The granules may contain disintegrants, eg an effervescent couple formed from an acid and a carbonate or bicarbonate salt to facilitate dispersion in the liquid medium.
The therapeutically active compounds of formula I may be formulated into a composition which the patient retains in his mouth so that the active compound is administered through the mucosa of the mouth.
Dosage forms suitable for rectal administration are the known pharmaceutical forms for such administration, for example, suppositories with cocoa butter or polyethylene glycol bases.
Dosage forms suitable for parenteral administration are the known pharmaceutical forms for such administration, for example sterile suspensions or sterile solutions in a suitable solvent.
Dosage forms for topical administration may comprise a matrix in which the pharmacologically active compounds of the present invention are dispersed so that the compounds are held in contact with the skin in order to administer the compounds transdermally. A suitable transdermal composition may be prepared by mixing the pharmaceutically active compound with a topical vehicle, such as a mineral oil, petrolatum and/or a wax, e.g. paraffin wax or beeswax, together with a potential transdermal accelerant such as dimethyl sulphoxide or propylene glycol. Alternatively the active compounds may be dispersed in a pharmaceutically acceptable cream, gel or ointment base. The amount of active compound contained in a topical formulation should be such that a therapeutically effective amount of the compound is delivered during the period of time for which the topical formulation is intended to be on the skin.
The therapeutically active compound of formula I may be formulated into a composition which is dispersed as an aerosol into the patients oral or nasal cavity. Such aerosols may be administered from a pump pack or from a pressurised pack containing a volatile propellant.
The therapeutically active compounds of formula I used in the method of the present invention may also be administered by continuous infusion either from an external source, for example by intravenous infusion or from a source of the compound placed within the body. Internal sources include implanted reservoirs containing the compound to be infused which is continuously released for example by osmosis and implants which may be (a) liquid such as an oily suspension of the compound to be infused for example in the form of a very sparingly water-soluble derivative such as a dodecanoate salt or a lipophilic ester or (b) solid in the form of an implanted support, for example of a synthetic resin or waxy material, for the compound to be infused. The support may be a single body containing all the compound or a series of several bodies each containing part of the compound to be delivered. The amount of active compound present in an internal source should be such that a therapeutically effective amount of the compound is delivered over a long period of time.
In some formulations it may be beneficial to use the compounds of the present invention in the form of particles of very small size, for example as obtained by fluid energy milling.
In the compositions of the present invention the active compound may, if desired, be associated with other compatible pharmacologically active ingredients. The invention further provides the use of compounds of formula I in the manufacture of a medicament for aiding in weight loss after pregnancy.
In another aspect, the invention further provides a pharmaceutical composition for aiding in weight loss after pregnancy, comprising a compound of formula I in conjunction with a pharmaceutically acceptable diluent or carrier.
Pregnancy can result in excessive weight gain and retention. A certain amount of weight gain during pregnancy is desirable. However weight gain beyond the desired amount is predominantly maternal adipose tissue. It is this fat tissue that, in large measure, accounts for the postpartum retention weight gained during pregnancy. This retention reflects a postpartum energy balance that does not lead to catabolism of the gained adipose tissues. Administration of a compound of Formula I helps to change the energy balance.
Monoamine reuptake inhibitors have been used to treat certain of the disorders described in the present invention. However, these compounds are known to suffer from a number of disadvantages. Firstly such compounds are not effective in all patients. Secondly where the compounds are effective they may not provide a complete cure of the disorder. Thirdly, there are many undesirable side-effects known with this type of compound. Such side-effects include nausea, sexual dysfunction, light headedness, somnolence, sweating, tremor, dry mouth, asthenia, insomnia, diarrhoea, headache, vomiting, anxiety, drowsiness, dizziness, fever, rash or allergic reactions, arthralgia, myalgia, convulsions, hypomania and mania.
Sibutramine (Formula I, R1 = CH3 ι R2 = CH3) has a pharmacological profile which is unique amongst monoamine reuptake inhibitors. Through its pharmacologically active metabolites, (metabolite 1 , R^ = H, R2 = CH3 in Formula I and metabolite 2, R-i = H, R2 = H in Formula I) sibutramine inhibits the reuptake of all three monoamines differentiating it from serotonin (δ-HT)-selective reuptake inhibitors, e.g. fluoxetine, noradenaline-selective reuptake inhibitors, e.g. desipramine, dopamine-selective reuptake inhibitors, e.g. bupropion, and serotonin-noradenaline reuptake inhibitors, e.g. venlafaxine (Table 1). It is this unique combination of pharmacological actions which renders sibutramine, and the other compounds of formula I, efficacious in aiding weight loss after pregnancy.
The assays below are performed in a similar manner to those described in WO98/41528.
TABLE
Comparison of the in vitro monoamine reuptake inhibition profiles of Examples 1 and 2, and various reference monoamine reuptake inhibitors in rat brain tissue
Figure imgf000010_0001
The results are the means of >3 separate determinations
Example 1 R-\ = H R2 = CH3 in Formula I Example 2 R^ = H R2 = H in Formula I
The efficacy of compounds of formula I in treating postpartum retention of weight is demonstrable through clinical trials in a relevant population set.
The invention has been described with reference to various specific embodiments. However, many variations and modifications may be made while remaining within the scope and spirit of the invention.

Claims

Claims
1. A method of aiding postpartum weight loss comprising administering to a human in need thereof a therapeutically effective amount of a compound of formula I
CH„
Figure imgf000012_0001
including enantiomers and pharmaceutically acceptable salts thereof in which R, and R2 are independently H or methyl, in conjunction with a pharmaceutically acceptable diluent or carrier.
2. A method as claimed in claim 1 in which the postpartum weight loss is associated with maternal adipose tissue.
3. A method as claimed in claim 1 or 2 wherein the compound of formula I is N, N-dimethyl-1 -[1 -(4-chlorophenyl)cyclobutyl]-3-methylbutylamine hydrochloride.
4. A method as claimed in claim 1 or 2 wherein the compound of formula I is N, N-dimethyl-1 -[1 -(4-chlorophenyl)cyclobutyl]-3-methylbutylamine hydrochloride in the form of its monohydrate.
5. A method as claimed in claim 1 or 2 wherein the compound of formula 1 is (+)-N-[1 -[1 -(4-chlorophenyl)cyclobutyl]-3-methylbutyl}-N-methylamine.
6. A method as claimed in claim 1 or 2 wherein the compound of formula 1 is (-)-N-{1-[1-(4-chlorophenyl)cyclobutyl-3-methylbutyl}-N-methylamine.
7. A method as claimed in claim 1 or 2 wherein the compound of formula 1 is (+)-1 -[1 -(4-chlorophenyl)cyclobutyl]-3-methylbutylamine.
8. A method as claimed in claim 1 or 2 wherein the compound of formula 1 is (-)-1 -[1 -(4-chlorophenyl)cyclobutyl]-3-methylbutylamine.
9 A method as claimed in claim 1 or 2 wherein the compound of formula 1 is
(+)-N-{1-[1-(4-chlorophenyl)cyclobutyl]-3-methylbutyl}-N-N-dimethylamine.
10. The method as claimed in claim 1 or 2 wherein the compound of formula I is (-)-N-{1 -[1 -(4-chlorophenyl)cyclobutyl]-3-methylbutyl}-N-N-dimethylamine.
11. The method as claimed in claim 1 or 2 wherein the compound of formula I is (±)-N-{1 -[1 -(4-chlorophenyl)cyclobutyl-3-methylbutyl}-N-methylamine.
12. The method as claimed in claim 1 or 2 wherein the compound of formula I is (±)-1 -[1 -(4-chlorophenyl)cyclobutyl]-3-methylbutylamine.
13. The method as claimed in claim 1 or 2 wherein the compound of formula I is (±)-N-{1 -[1 -(4-chlorophenyl)cyclobutyl]-3-methylbutyl}-N-N-dimethylamine.
14. The use of a compound of formula I
CH-
Figure imgf000013_0001
including enantiomers and pharmaceutically acceptable salts thereof in which R-, and R2 are independently H or methyl, in the manufacture of a medicament for aiding in the postpartum weigh loss associated with a pregnancy
15. The use as claimed in claim 14 in which the weight gain is associated with maternal adipose tissue.
16. The use as claimed in claim 14 or15 in which the compound of formula I is N, N-dimethyl-1 -[1 -(4-chlorophenyl)cyclobutyl]-3-methylbutylamine hydrochloride.
17. The use as claimed in claim 14 or 15 in which the compound of formula I is N, N-dimethyl-1 -[1 -(4-chlorophenyl)cyclobutyl]-3-methylbutylamine hydrochloride monohydrate.
18. A pharmaceutical composition for use in postpartum weight loss, comprising a therapeutically effective amount of a compound of formula I
CH,
Figure imgf000014_0001
including enantiomers and pharmaceutically acceptable salts thereof in which R<, and R2 are independently H or methyl, in conjunction with a pharmaceutically acceptable diluent or carrier.
19. A pharmaceutical composition as claimed in claim 18 in which the compound of formula I is N,N-dimethyl-1-[1-(4-chlorophenyl)cyclobutyl]-3- methylbutylamine hydrochloride.
20. A pharmaceutical composition as claimed in claim 18 in which the compound of formula I is N, N-dimethyl-1 -[1-(4-chlorophenyl)cyclobutyl]-3- methylbutylamine hydrochloride monohydrate.
PCT/US2000/007202 1999-03-19 2000-03-17 Weight loss after pregnancy WO2000056317A1 (en)

Priority Applications (12)

Application Number Priority Date Filing Date Title
PL00351080A PL351080A1 (en) 1999-03-19 2000-03-17 Weight loss after pregnancy
MXPA01009465A MXPA01009465A (en) 1999-03-19 2000-03-17 Weight loss after pregnancy.
IL14524300A IL145243A0 (en) 1999-03-19 2000-03-17 Weight loss after pregnancy
CA002367268A CA2367268A1 (en) 1999-03-19 2000-03-17 Weight loss after pregnancy
BR0009078-6A BR0009078A (en) 1999-03-19 2000-03-17 Weight loss after pregnancy
KR1020017011956A KR20010113848A (en) 1999-03-19 2000-03-17 Weight loss after pregnancy
AU41729/00A AU4172900A (en) 1999-03-19 2000-03-17 Weight loss after pregnancy
SK1336-2001A SK13362001A3 (en) 1999-03-19 2000-03-17 Use of a compound and pharmaceutical composition comprising such a compound
EP00921401A EP1162966A4 (en) 1999-03-19 2000-03-17 Weight loss after pregnancy
JP2000606222A JP2002539253A (en) 1999-03-19 2000-03-17 Weight loss after pregnancy
NO20014474A NO20014474L (en) 1999-03-19 2001-09-14 Weight loss after pregnancy
BG105995A BG105995A (en) 1999-03-19 2001-10-10 Weight loss after pregnancy

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US12514999P 1999-03-19 1999-03-19
US60/125,149 1999-03-19

Publications (1)

Publication Number Publication Date
WO2000056317A1 true WO2000056317A1 (en) 2000-09-28

Family

ID=22418407

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2000/007202 WO2000056317A1 (en) 1999-03-19 2000-03-17 Weight loss after pregnancy

Country Status (19)

Country Link
EP (1) EP1162966A4 (en)
JP (1) JP2002539253A (en)
KR (1) KR20010113848A (en)
CN (1) CN1352553A (en)
AU (1) AU4172900A (en)
BG (1) BG105995A (en)
BR (1) BR0009078A (en)
CA (1) CA2367268A1 (en)
CZ (1) CZ20013282A3 (en)
HU (1) HUP0200500A2 (en)
IL (1) IL145243A0 (en)
MX (1) MXPA01009465A (en)
NO (1) NO20014474L (en)
NZ (1) NZ514015A (en)
PL (1) PL351080A1 (en)
SK (1) SK13362001A3 (en)
TR (1) TR200102694T2 (en)
WO (1) WO2000056317A1 (en)
ZA (1) ZA200107680B (en)

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5436272A (en) * 1988-11-29 1995-07-25 The Boots Company (Usa), Inc. Treatment of obesity

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19518988A1 (en) * 1995-05-29 1996-12-05 Basf Ag Use of aryl substituted cyclobutylalkylamines to treat obesity

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5436272A (en) * 1988-11-29 1995-07-25 The Boots Company (Usa), Inc. Treatment of obesity

Also Published As

Publication number Publication date
ZA200107680B (en) 2003-06-18
EP1162966A4 (en) 2002-06-12
NO20014474D0 (en) 2001-09-14
IL145243A0 (en) 2002-06-30
BG105995A (en) 2002-06-28
BR0009078A (en) 2001-12-26
EP1162966A1 (en) 2001-12-19
PL351080A1 (en) 2003-03-10
KR20010113848A (en) 2001-12-28
JP2002539253A (en) 2002-11-19
NZ514015A (en) 2001-09-28
CA2367268A1 (en) 2000-09-28
NO20014474L (en) 2001-11-14
CZ20013282A3 (en) 2002-07-17
SK13362001A3 (en) 2002-07-02
AU4172900A (en) 2000-10-09
TR200102694T2 (en) 2002-04-22
MXPA01009465A (en) 2004-03-19
HUP0200500A2 (en) 2002-08-28
CN1352553A (en) 2002-06-05

Similar Documents

Publication Publication Date Title
AU773188C (en) Method of treating eating disorders
US6376553B1 (en) Treatment of pain
WO2000056309A1 (en) Method of treating sexual dysfunction
WO2000056318A1 (en) Treatment of neuropathic pain or fibromyalgia
WO2000056149A1 (en) Method of treating anxiety disorders
US6376551B1 (en) Treatment of chronic fatigue syndrome
US6441046B1 (en) Control of metabolism
WO2000056320A1 (en) Treatment of menstrual function
US6232347B1 (en) Treatment of osteoarthritis
US6380260B1 (en) Treatment to lower platelet adhesiveness
AU773490B2 (en) Treatment of osteoarthritis
US6365632B1 (en) Treatment of orthostatic hypotension
WO2000056150A1 (en) Treatment of premenstrual syndrome
WO2000056148A1 (en) Treatment of pharmacology of drug misuse and other addictive disorders
US20040198837A1 (en) Treatment of neuropathic pain or fibromyalgia
US6288125B1 (en) Treatment of hiatial hernia
CA2366652A1 (en) Treatment of pulmonary hypertension
US20030013735A1 (en) Weight loss after pregnancy
US20020132856A1 (en) Treatment of premenstrual syndrome
WO2000056307A1 (en) Treatment of hiatial hernia
EP1162966A1 (en) Weight loss after pregnancy
WO2000056308A1 (en) Prevention of cardiovascular disease
EP1171106A1 (en) Treatment of certain cancers associated with weight gain

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 00807535.2

Country of ref document: CN

AK Designated states

Kind code of ref document: A1

Designated state(s): AT AU BG BR CA CN CZ DE DK ES FI GB HR HU ID IL IN IS JP KR LT LU LV MX NO NZ PL PT RO RU SE SG SI SK TR UA

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 514015

Country of ref document: NZ

WWE Wipo information: entry into national phase

Ref document number: PV2001-3282

Country of ref document: CZ

ENP Entry into the national phase

Ref document number: 2000 606222

Country of ref document: JP

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: IN/PCT/2001/01121/MU

Country of ref document: IN

ENP Entry into the national phase

Ref document number: 2367268

Country of ref document: CA

Ref document number: 2367268

Country of ref document: CA

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 2001/07680

Country of ref document: ZA

Ref document number: 13362001

Country of ref document: SK

Ref document number: 200107680

Country of ref document: ZA

Ref document number: 2001/02694

Country of ref document: TR

WWE Wipo information: entry into national phase

Ref document number: 2000921401

Country of ref document: EP

Ref document number: 1020017011956

Country of ref document: KR

Ref document number: PA/a/2001/009465

Country of ref document: MX

ENP Entry into the national phase

Ref document number: 2000 105995

Country of ref document: BG

Kind code of ref document: A

WWP Wipo information: published in national office

Ref document number: 2000921401

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1020017011956

Country of ref document: KR

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWP Wipo information: published in national office

Ref document number: PV2001-3282

Country of ref document: CZ

WWW Wipo information: withdrawn in national office

Ref document number: 2000921401

Country of ref document: EP

WWR Wipo information: refused in national office

Ref document number: PV2001-3282

Country of ref document: CZ

WWW Wipo information: withdrawn in national office

Ref document number: 1020017011956

Country of ref document: KR